Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Robert Azelby


  • President And Ceo at Alder Biopharmaceuticals Inc (ALDR), 2019-10-24
  • Director at Clovis Oncology Inc. (CLVS), 2019-06-07
  • Director at Cascadian Therapeutics Inc. (CASC), 2018-03-13
  • Evp & Chief Commercial Officer at Juno Therapeutics Inc. (JUNO), 2018-03-07
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
JUNO $85.55 4,159 Officer 89,612 2018-02-12 Filing
JUNO $85.55 4,157 Officer 89,614 2018-02-12 Filing
JUNO $85.77 3,497 Officer 93,771 2018-02-08 Filing
JUNO $85.78 4,167 Officer 96,471 2018-02-01 Filing
JUNO $86.25 102,539 Officer 70,832 2018-01-22 Filing